Literature DB >> 7118489

Middle molecular substances in acute renal failure.

M Mydlík, V Spustová, R Dzúrik, K Derzsiová.   

Abstract

The changes of middle molecular substances (MMS) in a group of 13 patients with acute renal failure of various origin were determined by gel filtration on Sephadex G 15. The concentrations of plasma middle molecular substances increased rapidly during the oliguric phase and decreased during the diuretic phase of acute renal failure. However, it was significantly higher than in the controls. The concentration of MMS in the convalescent phase was still increased. In the oliguric phase of acute renal failure, before and 4 hours after haemodialysis a direct dependence was found between fraction 5 and serum urea. In the oliguric phase, this occurred between fraction 6 and serum urea. In the diuretic phase a direct dependence was demonstrated between fraction 4 and serum urea, as well as serum creatinine. It was found that MMS are contributing to the development of uraemic syndrome in acute renal failure.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7118489     DOI: 10.1007/bf02082386

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  10 in total

1.  Chemical composition and rate of passage across semipermeable membranes of basic peptides isolated from peritoneal dialysis fluid from patients with chronic renal failure.

Authors:  W Lutz
Journal:  Acta Med Pol       Date:  1976

2.  [Mean molecular substance volume in the sera of patients after kidney transplant operation (author's transl)].

Authors:  P Bozek; R Dzúrik; H Danĕková; J Reznícek; V Zvara
Journal:  Cas Lek Cesk       Date:  1977-01-14

3.  The effect of hemodialysis on endogenous middle molecules in uremic patients.

Authors:  H Asaba; P Fürst; R Oulés; V Yahiel; L Zimmerman; J Bergström
Journal:  Clin Nephrol       Date:  1979-05       Impact factor: 0.975

4.  Uremic middle molecules exist and are biologically active.

Authors:  J Bergström; P Fürst; L Zimmerman
Journal:  Clin Nephrol       Date:  1979-05       Impact factor: 0.975

5.  Middle-sized ninhydrin-positive molecules in uraemic patients treated by repeated haemodialysis. I. Preliminary characteristics.

Authors:  Z Hanicki; M Sarnecka-Keller; A Klein; K Slizowska
Journal:  Clin Chim Acta       Date:  1974-07-15       Impact factor: 3.786

6.  Bi-directional permeability of the human peritoneum to middle molecules.

Authors:  A L Babb; P J Johansen; M J Strand; H Tenckhoff; B H Scribner
Journal:  Proc Eur Dial Transplant Assoc       Date:  1973

7.  Blood level of middle molecular substances during uraemia and haemodialysis.

Authors:  R Dzúrik; P Bozek; J Reznícek; A Oborníková
Journal:  Proc Eur Dial Transplant Assoc       Date:  1973

8.  Removal of endogenous middle molecules by hemoperfusion.

Authors:  H Asaba; J Bergström; P Fürst; B Gunnarsson; M Neuhauser; R Oulès; V Yahiel
Journal:  Artif Organs       Date:  1979-05       Impact factor: 3.094

9.  "Middle molecules" in acute experimental uremia.

Authors:  W Lutz; K Madry; G Grande
Journal:  Acta Med Pol       Date:  1978

10.  Serum and ultradiafiltrate middle molecules in hemodialysed patients.

Authors:  P Bozek; J Erben; J Zahradnik; R Dzúrik
Journal:  Int Urol Nephrol       Date:  1979       Impact factor: 2.370

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.